Neurocardiogenic syncope: Latest pharmacological therapies

Lin Y. Chen, Win Kuang Shen

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Neurocardiogenic syncope is a neurally mediated disorder and is a common cause of syncope. The goal of treatment is to prevent recurrences with the aim of improving quality of life and reducing morbidity. Reassurance, in some cases, may suffice. In others, augmenting central blood volume by increasing fluid and/or salt intake is effective. The role of non-pharmacological physical manoeuvres is increasingly recognised, given the increasing clinical trial data supporting their efficacy. This review summarises the clinical evidence for a variety of pharmacological agents. Of these, midodrine appears to have yielded the most consistent favourable outcome. Its use, however, should be reserved for patients with recurrent and refractory syncope.

Original languageEnglish (US)
Pages (from-to)1151-1162
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Issue number9
StatePublished - Jun 1 2006


  • Midodrine
  • Neurocardiogenic syncope
  • β-blockers

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Neurocardiogenic syncope: Latest pharmacological therapies'. Together they form a unique fingerprint.

Cite this